Literature DB >> 22930691

Overexpression of the DMP1 C-terminal fragment stimulates FGF23 and exacerbates the hypophosphatemic rickets phenotype in Hyp mice.

A Martin1, V David, H Li, B Dai, J Q Feng, L D Quarles.   

Abstract

Dentin matrix protein-1 (DMP1) or phosphate-regulating gene with homologies to endopeptidases on the X chromosome (PHEX) inactivation results in elevation of the phosphaturic hormone fibroblast growth factor (FGF)-23, leading to hypophosphatemia, aberrant vitamin D metabolism, and rickets/osteomalacia. Compound mutant Phex-deficient Hyp and Dmp1(ko) mice exhibit nonadditive phenotypes, suggesting that DMP1 and PHEX may have interdependent effects to regulate FGF23 and bone mineralization. To determine the relative importance of DMP1 and PHEX in regulating FGF23 and mineralization, we tested whether the transgenic expression of full-length [Dmp1(Tg(full-length))] or C-terminal Dmp1 [Dmp1(Tg(57kDa))] could rescue the phenotype of Hyp mice. We found that Dmp1(ko) and Hyp mice have similar phenotypes characterized by decreased cortical bone mineral density (-35% vs. wild type, P < 0.05) and increased serum FGF23 levels (~12-fold vs. wild type, P < 0.05). This was significantly corrected by the overexpression of either the full-length or the C-terminal transgene in Dmp1(ko) mice. However, neither of the transgenes rescued the Hyp mice phenotype. Hyp/Dmp1(Tg(full-length)) and Hyp mice were similar, but Hyp/Dmp1(Tg(57 kDa)) mice exhibited worsening of osteomalacia (-20% cortical bone mineral density) in association with increased serum FGF23 levels (+2-fold) compared with Hyp mice. Bone FGF23 mRNA expression was decreased and a 2-fold increase in the ratio of the full-length/degraded circulating FGF23 was observed, indicating that degradation of FGF23 was impaired in Hyp/Dmp1(Tg(57 kDa)) mice. The paradoxical effects of the C-terminal Dmp1 transgene were observed in Hyp/Dmp1(Tg(57 kDa)) but not in Dmp1(Tg(57 kDa)) mice expressing a functional PHEX. These findings indicate a functional interaction between PHEX and DMP1 to regulate bone mineralization and circulating FGF23 levels and for the first time demonstrate effects of the C-terminal DMP1 to regulate FGF23 degradation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22930691      PMCID: PMC3487625          DOI: 10.1210/me.2012-1062

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  38 in total

1.  A Phex mutation in a murine model of X-linked hypophosphatemia alters phosphate responsiveness of bone cells.

Authors:  Shoji Ichikawa; Anthony M Austin; Amie K Gray; Michael J Econs
Journal:  J Bone Miner Res       Date:  2012-02       Impact factor: 6.741

2.  Use of the transgenic approach to determine the role of DMP1 in phosphate regulation.

Authors:  Y Lu; S Liu; Y Xie; S Yu; L Quarles; L F Bonewald; J Q Feng
Journal:  J Musculoskelet Neuronal Interact       Date:  2007 Oct-Dec       Impact factor: 2.041

Review 3.  Endocrine functions of bone in mineral metabolism regulation.

Authors:  L Darryl Quarles
Journal:  J Clin Invest       Date:  2008-12-01       Impact factor: 14.808

4.  Impaired energetic metabolism after central leptin signaling leads to massive appendicular bone loss in hindlimb-suspended rats.

Authors:  Aline Martin; Valentin David; Laurence Vico; Thierry Thomas
Journal:  J Bone Miner Res       Date:  2008-12       Impact factor: 6.741

5.  Degradation of MEPE, DMP1, and release of SIBLING ASARM-peptides (minhibins): ASARM-peptide(s) are directly responsible for defective mineralization in HYP.

Authors:  Aline Martin; Valentin David; Jennifer S Laurence; Patricia M Schwarz; Eileen M Lafer; Anne-Marie Hedge; Peter S N Rowe
Journal:  Endocrinology       Date:  2007-12-27       Impact factor: 4.736

6.  MEPE-ASARM peptides control extracellular matrix mineralization by binding to hydroxyapatite: an inhibition regulated by PHEX cleavage of ASARM.

Authors:  William N Addison; Yukiko Nakano; Thomas Loisel; Phillippe Crine; Marc D McKee
Journal:  J Bone Miner Res       Date:  2008-10       Impact factor: 6.741

7.  Studies of the DMP1 57-kDa functional domain both in vivo and in vitro.

Authors:  Yongbo Lu; Chunlin Qin; Yixia Xie; Lynda F Bonewald; Jian Q Feng
Journal:  Cells Tissues Organs       Date:  2008-08-26       Impact factor: 2.481

8.  Pathogenic role of Fgf23 in Dmp1-null mice.

Authors:  Shiguang Liu; Jianping Zhou; Wen Tang; Rochelle Menard; Jian Q Feng; L D Quarles
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-06-17       Impact factor: 4.310

9.  Matrix extracellular phosphoglycoprotein (MEPE) is a new bone renal hormone and vascularization modulator.

Authors:  Valentin David; Aline Martin; Anne-Marie Hedge; Peter S N Rowe
Journal:  Endocrinology       Date:  2009-06-11       Impact factor: 4.736

10.  The PHEX transgene corrects mineralization defects in 9-month-old hypophosphatemic mice.

Authors:  Adele Boskey; Aaron Frank; Yukiji Fujimoto; Lyudmila Spevak; Kostas Verdelis; Bruce Ellis; Nancy Troiano; William Philbrick; Thomas Carpenter
Journal:  Calcif Tissue Int       Date:  2008-12-12       Impact factor: 4.333

View more
  19 in total

Review 1.  FGF23 and Phosphate Wasting Disorders.

Authors:  Xianglan Huang; Yan Jiang; Weibo Xia
Journal:  Bone Res       Date:  2013-06-28       Impact factor: 13.567

Review 2.  The rachitic tooth.

Authors:  Brian L Foster; Francisco H Nociti; Martha J Somerman
Journal:  Endocr Rev       Date:  2013-12-04       Impact factor: 19.871

3.  Genetic background influences cardiac phenotype in murine chronic kidney disease.

Authors:  Samantha Neuburg; Corey Dussold; Claire Gerber; Xueyan Wang; Connor Francis; Lixin Qi; Valentin David; Myles Wolf; Aline Martin
Journal:  Nephrol Dial Transplant       Date:  2018-07-01       Impact factor: 5.992

4.  A Mutation in the Dmp1 Gene Alters Phosphate Responsiveness in Mice.

Authors:  Shoji Ichikawa; Rita L Gerard-O'Riley; Dena Acton; Amie K McQueen; Isabel E Strobel; Phillip C Witcher; Jian Q Feng; Michael J Econs
Journal:  Endocrinology       Date:  2017-03-01       Impact factor: 4.736

5.  Fibroblast Growth Factor 23 Regulation by Systemic and Local Osteoblast-Synthesized 1,25-Dihydroxyvitamin D.

Authors:  Loan Nguyen-Yamamoto; Andrew C Karaplis; Rene St-Arnaud; David Goltzman
Journal:  J Am Soc Nephrol       Date:  2016-08-17       Impact factor: 10.121

Review 6.  Inflammation regulates fibroblast growth factor 23 production.

Authors:  Connor Francis; Valentin David
Journal:  Curr Opin Nephrol Hypertens       Date:  2016-07       Impact factor: 2.894

7.  Functional heterogeneity of osteocytes in FGF23 production: the possible involvement of DMP1 as a direct negative regulator.

Authors:  Ji-Won Lee; Akira Yamaguchi; Tadahiro Iimura
Journal:  Bonekey Rep       Date:  2014-06-04

8.  Hypophosphatemic rickets accelerate chondrogenesis and cell trans-differentiation from TMJ chondrocytes into bone cells via a sharp increase in β-catenin.

Authors:  Hui Li; Yan Jing; Rong Zhang; Qi Zhang; Jun Wang; Aline Martin; Jian Q Feng
Journal:  Bone       Date:  2019-11-18       Impact factor: 4.398

9.  Conditional mesenchymal disruption of pkd1 results in osteopenia and polycystic kidney disease.

Authors:  Ni Qiu; Zhousheng Xiao; Li Cao; Valentin David; Leigh Darryl Quarles
Journal:  PLoS One       Date:  2012-09-21       Impact factor: 3.240

Review 10.  The Role of DMP1 in CKD-MBD.

Authors:  Aline Martin; Dominik Kentrup
Journal:  Curr Osteoporos Rep       Date:  2021-07-31       Impact factor: 5.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.